Epidermal growth factor receptor (EGFR) gene mutations (G719X, exon 19
deletions/insertions, L858R, and L861Q) predict favorable responses to EGFR tyrosine …

Lung cancer is the leading cause of cancer-related death. The identification of epidermal
growth factor receptor (EGFR) somatic mutations defined a new, molecularly classified …

Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …

The discovery of mutations in the tyrosine kinase domain of the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) accelerated the research of …

Lung cancer leads cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC),
the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced …

Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …

Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …

Aims Deletion of exon 19 of the epidermal growth factor receptor (EGFR) and mutation of
exon 21 are the most common EGFR mutations and predict higher response to EGFR …

Purpose: Epidermal growth factor receptor (EGFR) genotyping is now standard in the
management of advanced lung adenocarcinoma, as this biomarker predicts marked benefit …

Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …